Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Not yet recruiting · NCT07447817 · Registry updated 2026-03-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias | Cytopenia, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, anemia, blood platelet disease, bone marrow disorder, hematologic disorder, primary myelofibrosis, thrombocytopenia | Not yet recruiting | Phase 2 | 2026-03-18 | NCT07447817 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| John Mascarenhas | 3 |
| Karyopharm Therapeutics Inc | 25 |
| National Cancer Institute (NCI) | 3015 |
| Sobi, Inc. | 12 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | New York | United States | 342 |
| The University of Kansas Cancer Center-Westwood | Westwood | United States | 2 |
| Wake Forest Baptist Health Comprehensive Cancer Center | Winston-Salem | United States | 3 |